OTTMUSG00000002045 Inhibitors

Chemical inhibitors of transmembrane protein 92-like operate through various pathways, potentially leading to its functional inhibition. LY294002 and Wortmannin, as PI3K inhibitors, disrupt the PI3K/AKT pathway, a crucial signaling axis for cellular survival and proliferation. This disruption could lead to the inhibition of transmembrane protein 92-like by altering the intracellular environment. Rapamycin and PP242, targeting the mTOR signaling pathway, modulate processes like protein synthesis and autophagy, which could indirectly affect the function of transmembrane protein 92-like. Torin 1 also targets mTOR but affects both mTORC1 and mTORC2 complexes, potentially impacting the protein's functional state through changes in cellular growth and survival.

The MAPK/ERK pathway, targeted by PD98059, U0126, Selumetinib, and PD0325901, represents another critical route for potential inhibition. These inhibitors disrupt MEK and the MAPK/ERK signaling, potentially leading to changes in gene expression and cellular differentiation processes that could indirectly affect transmembrane protein 92-like. SB203580 and SP600125, inhibiting p38 MAPK and JNK respectively, might inhibit the protein by altering cellular stress responses and apoptotic pathways. Dactolisib, with dual inhibitory action on PI3K and mTOR pathways, represents a broader approach, potentially leading to the inhibition of transmembrane protein 92-like by changing cellular dynamics related to proliferation and survival. These chemicals, through their targeted action on specific signaling pathways, collectively contribute to the potential functional inhibition of transmembrane protein 92-like, demonstrating the complex interplay of cellular signaling networks.